Abstract:Sclerostin,a protein encoded by sclerosteosis(SOST) gene,antagonizes the Wnt protein via the low density lipoprotein receptor-related protein(LRP5/6) receptor and inhibits bone formation.It has been a new target for the treatment of osteoporosis.Both basic and clinical researches have indicated that sclerostin monoclonal antibody can treat osteoporosis by increasing bone mineral density,promoting bone formation and inhibiting bone resorption.However,limited data have evaluated the adverse effects of sclerostin monoclonal antibody and its influence on bone fracture,which deserve further studies.

Research progress on the effect of sclerostin monoclonal antibody in treating osteoporosis